Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer using a multi-marker panel and a machine-learning approach: Final results of the prospective multicenter PERMAD trial.
Authors
Hans A. Kestler
Ulm University - Institute of Medical Systems Biology, Ulm, Germany
Hans A. Kestler , Thomas Jens Ettrich , Alexander Stein , Dirk Arnold , Gerald W. Prager , Stefan Kasper , Michael Niedermeier , Lothar Müller , Stefan Kubicka , Alexander Koenig , Petra Buechner-Steudel , Andreas Berger , Kai Wille , Angelika Kestler , Johann M. Kraus , Silke Werle , Lukas Perkhofer , Ludwig Lausser , Thomas Seufferlein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02331927
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 204)
DOI
10.1200/JCO.2024.42.3_suppl.204
Abstract #
204
Poster Bd #
M12
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: Final results of the multicenter, international PERMAD trial.
First Author: Thomas Seufferlein
Poster
2020 Gastrointestinal Cancers Symposium
Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line anti-EGFR or anti-VEGF therapy, tumour sidedness, and survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry.
First Author: Tharani Krishnan